Does Medicare cover Ozempic, Wegovy or Zepbound?

This is the fastest-moving coverage question in Medicare right now, and it is also the one where families get the most contradictory answers — from pharmacies, from plan call centres, and from each other. The confusion is not anybody's fault. Two drugs can contain the identical molecule, be made by the same company, and have completely different Medicare coverage, because Medicare pays attention to what a drug is approved to treat rather than what is in it.

Once you understand that one idea, the rest of this falls into place.

When Part D was written, Congress copied over a list of drug categories that plans were allowed to exclude, and agents used for weight loss were on it. That exclusion is statutory. It is not a decision any plan made, and no appeal will overturn it — changing it permanently would take an act of Congress.

So semaglutide sold as Ozempic, approved to treat type 2 diabetes, has always been coverable under Part D. The same molecule sold as Wegovy, approved for weight management, was not. Families would discover this at the pharmacy counter and reasonably conclude someone had made a mistake. Nobody had.

CMS used its demonstration authority to create a workaround called the Medicare GLP-1 Bridge. It began on 1 July 2026 and is currently scheduled to end on 31 December 2027. It deliberately sits outside the Part D benefit — which is how it avoids the statutory exclusion, and also the source of most of its quirks.

This is the part almost nobody explains, and it is the difference between a straightforward fill and weeks of back-and-forth. Before anything goes to the Bridge, the prescriber has to establish whether your parent has a diagnosis that already makes the drug coverable under ordinary Part D rules. Those diagnoses are:

• Type 2 diabetes.
• Moderate to severe obstructive sleep apnea.
• Noncirrhotic metabolic dysfunction-associated steatohepatitis — MASH — with moderate to advanced liver scarring.
• Established cardiovascular disease, where the drug is prescribed to reduce the risk of heart attack and stroke.

If any of those apply, the request must go to your parent's own Part D plan, not to the Bridge. The Bridge exists only for people whose prescription is genuinely for reducing and maintaining weight, without one of these qualifying conditions on the chart.

That is worth sitting with, because it inverts the usual advice. A parent with type 2 diabetes is in the better position here, not the worse one — their route runs through regular Part D coverage, which counts toward their deductible and their out-of-pocket cap. The Bridge, as you are about to see, does not.

The copay is a flat $50 for a one-month supply, and it is the same $50 regardless of income. That last part sounds fair and is actually the program's sharpest edge. Because the Bridge operates outside the Part D benefit:

• The $50 does not count toward the Part D deductible.
• It does not count toward the annual out-of-pocket cap, so it does not move your parent any closer to the point where their other drugs become free.
• Extra Help — the low-income subsidy — does not apply. A beneficiary who pays almost nothing for their other prescriptions still pays the full $50 here.
• These drugs cannot be spread across the year using the Medicare Prescription Payment Plan.

For someone paying list price, $50 a month is a dramatic improvement. For someone on Extra Help who is used to a few dollars a prescription, it is a real monthly cost that arrives on top of everything else, and it is worth deciding deliberately rather than discovering in month three.

1. 1.Your parent has to be enrolled in a Part D plan. The Bridge does not replace that requirement, even though it pays outside the plan.
2. 2.The prescriber writes the prescription with an obesity diagnosis and sends it to the pharmacy, flagged for the Bridge.
3. 3.The pharmacy submits the claim and it is denied. This is by design — the denial is what opens the door to the prior authorization, so do not treat it as a rejection.
4. 4.The prescriber then submits a prior authorization request to CMS, electronically or by fax. In 2026 a single central processor handles all of this rather than the individual plans.
5. 5.Medicare sends your parent a letter confirming coverage, and the medicine can be collected for $50.

The Bridge is a demonstration, not a benefit. It is authorised through 31 December 2027. A longer-term replacement was announced alongside it — the BALANCE model — but the Part D portion of that has been delayed indefinitely, which is why the Bridge was extended in the first place.

In practice that means a family starting one of these drugs today should have a conversation with the prescriber about what happens if the program is not renewed. For some people the honest answer is that the drug becomes unaffordable and the weight returns. That is not a reason to avoid starting. It is a reason to know it now rather than in December 2027, and to revisit the question of whether a qualifying diagnosis has developed in the meantime — because a diagnosis that moves the prescription onto regular Part D coverage is the durable version of this.